drugset / Trial / NCT07522151

Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer

NCT07522151

Phase 3 Recruiting 874 enrolled Shanghai Shengdi Pharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate the efficacy, safety and tolerability of the two combination regimens.

Timeline

Start
2026-05-07
Primary completion
2029-12
Completion
2034-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody
Background Oxaliplatin Small molecule
Background S-1 Small molecule